Commission proposes JTI for innovative medicines
Brussels – The European Commission and the European Federation of Pharmaceutical Industry Associations, EFPIA, have launched a proposal to establish the European Union’s first Joint Technology Initiative on Innovative Medicines, IMI. According to the plan, which must now be adopted by the EU Council and the European Parliament, the Commission will invest a1 billion into IMI to streamline the drug development process over the next 7 years.
The investment will go entirely to small and medium-sized enterprises (SMEs) and universities for research that can be employed by the pharmaceutical sector. Another a1 billion will be invested by the pharmaceutical industry.
Projects will involve biomarker screening and in-vitro-, in-vivo and in-silico models to improve the prediction of drug safety and efficacy. If approved during the Portuguese EU presidency, it would be the first time that competing biopharmaceutical companies will work closely together with the aim of developing tools that improve the predictability of safety and efficacy of drug candidates. The first calls could be announced in 2008 at the earliest, according to an EFPIA spokesman.